Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 6.13B | 5.58B | 5.02B | 4.69B | 4.88B |
Gross Profit | 5.28B | 4.75B | 4.27B | 3.85B | 4.03B |
EBITDA | 4.27B | 3.79B | 3.37B | 3.03B | 3.10B |
Net Income | 3.53B | 3.23B | 2.69B | 2.64B | 2.11B |
Balance Sheet | |||||
Total Assets | 137.45B | 129.71B | 174.18B | 196.78B | 124.66B |
Cash, Cash Equivalents and Short-Term Investments | 3.01B | 3.02B | 2.82B | 2.95B | 1.73B |
Total Debt | 3.43B | 3.88B | 3.95B | 4.03B | 4.07B |
Total Liabilities | 110.96B | 102.97B | 147.44B | 169.56B | 98.31B |
Stockholders Equity | 26.49B | 26.74B | 26.88B | 27.40B | 26.32B |
Cash Flow | |||||
Free Cash Flow | 3.60B | 3.38B | 2.97B | 2.28B | 2.52B |
Operating Cash Flow | 3.69B | 3.45B | 3.06B | 2.40B | 2.72B |
Investing Cash Flow | -82.60M | 20.90M | -489.80M | 58.40M | -175.50M |
Financing Cash Flow | 5.08B | -48.34B | -25.38B | 69.91B | -2.46B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $162.81B | 41.27 | 11.68% | 0.70% | 12.98% | 42.72% | |
80 Outperform | $99.88B | 26.76 | 13.62% | 3.79% | 11.15% | 13.98% | |
80 Outperform | $25.75B | 32.24 | 18.93% | 1.02% | 15.76% | 1.97% | |
79 Outperform | $105.31B | 37.48 | 10.27% | 1.01% | 13.25% | 10.82% | |
79 Outperform | $92.30B | 43.16 | 55.18% | 0.70% | 11.47% | 16.14% | |
78 Outperform | $50.68B | 40.03 | 13.28% | 1.04% | 23.55% | 49.91% | |
68 Neutral | $17.10B | 11.19 | 9.70% | 3.58% | 11.11% | -4.55% |
On July 25, 2025, a jury ruled in favor of CME Group Inc. and the Board of Trade of the City of Chicago, Inc. in a class action lawsuit. The plaintiffs, Class B shareholders and members, alleged breaches of contract and good faith, but the verdict supported the defendants, potentially reinforcing their legal standing and shareholder relations.
The most recent analyst rating on (CME) stock is a Sell with a $191.00 price target. To see the full list of analyst forecasts on CME Group stock, see the CME Stock Forecast page.
CME Group Inc. held its 2025 Annual Meeting of Shareholders on May 8, 2025, where key proposals were voted on by shareholders. The election of fourteen Equity Directors was completed, with all nominees elected to serve until 2026. Additionally, the appointment of Ernst & Young LLP as the independent public accounting firm for 2025 was ratified, and the compensation of the company’s named executive officers was approved. However, no quorum was achieved for the election of Class B Directors, resulting in several directors continuing as ‘holdovers’ until the next election in 2026.